Epidemiological investigation of bloodstream infections by extended spectrum cephalosporin-resistant Escherichia coli in a Taiwanese teaching hospital.

Abstract	In an epidemiologic and case-control study including 30 case patients over a 3.5-year period in a Taiwanese university hospital, only beta-lactamase inhibitor use and extended-spectrum cephalosporin use were identified as independent risk factors for nosocomial CMY-2-producing Escherichia coli bloodstream infection, and CMY-2 producers were found more prevalent than extended-spectrum beta-lactamase-producing isolates.
Authors	Jing-Jou Yan, Wen-Chien Ko, Jiunn-Jong Wu, Shu-Huei Tsai, Chin-Luan Chuang
Journal	Journal of clinical microbiology (J Clin Microbiol) Vol. 42 Issue 7 Pg. 3329-32 (Jul 2004) ISSN: 0095-1137 [Print] United States
PMID	15243108 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	beta-lactamase CMY-2 beta-Lactamases
Topics	Adult Aged Bacteremia (epidemiology, etiology) Case-Control Studies Cephalosporin Resistance Escherichia coli (drug effects, enzymology) Escherichia coli Infections (epidemiology, etiology) Female Hospitals, Teaching Humans Male Middle Aged Random Amplified Polymorphic DNA Technique Risk Factors Taiwan (epidemiology) beta-Lactamases (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!